PIVOT-02: NKTR-214 & Nivolumab

PIVOT-02: NKTR-214 & Nivolumab

Episodes

Specialty:

All

Year:

All

EP. 1: Immunotherapy Progress in Oncology and the Role of IL-2

June 28th 2018

EP. 2: The PIVOT-02 Trial: NKTR-214 With Nivolumab

June 28th 2018

Trending on OncLive

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC

Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers

mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC

FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors